Clinical TrialJul 13, 2026, 04:22 PM
Erasca ERAS-0015 Shows 57% uORR8wk in Pancreatic Cancer
AI Summary
Erasca announced updated preliminary Phase 1 data for its pan-RAS molecular glue ERAS-0015 from the AURORAS-1 trial. The drug demonstrated encouraging monotherapy responses with a 57% uORR8wk in patients with 2L+ KRAS G12X pancreatic ductal adenocarcinoma and continued to be generally well-tolerated. The company also reported promising combination potential with panitumumab and is accelerating its potentially registration-enabling development plans for NSCLC and PDAC, with trials expected to begin in 2027 and early 2028.
Key Highlights
- ERAS-0015 showed 57% uORR8wk (N=7) at 32 mg QD in 2L+ KRAS G12X PDAC.
- Safety data remained consistent with prior disclosure, generally well-tolerated.
- Mostly low-grade TRAEs, no DLTs, and no discontinuations due to TRAEs.
- No DLTs observed in 16 mg combination cohort with panitumumab in colorectal cancer.
- Plans to initiate potentially registration-enabling trial in NSCLC in H1 2027.
- Plans to initiate Phase 3 pivotal trial in PDAC in 2027.
- Plans to initiate Phase 3 pivotal trial in RAS-mutant NSCLC in H2 2027 or H1 2028.
Price Impact
More from ERAS